FDA NOMINATION OF JANET WOODCOCK, MD, AS NEW CDER DIRECTOR
This article was originally published in The Tan Sheet
Executive Summary
FDA NOMINATION OF JANET WOODCOCK, MD, AS NEW CDER DIRECTOR is awaiting final clearance at HHS. Woodcock, currently director of FDA's Center for Biologics Evaluation & Research's Office of Therapeutics Research and Review, was selected from a short list of candidates for the Center for Drug Evaluation & Research post submitted by a search committee to Deputy Commissioner for Operations Jane Henney, MD, in early November.
You may also be interested in...
Woodcock Doesn't Want To Be Commissioner – But Has Some Ideas
CDER director believes some management improvements could be made in the executive suite, but she does not aspire to run FDA.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands